在患有MDS和TP53突变的患者中使用Decitabine-cedazuridine
Samuel Urrutia1, Koji Sasaki2, Alex Bataller2
1Washington University School of Medicine, Saint Louis, Missouri, United States.
Blood advances
|October 31, 2025
概括
患有骨髓发育综合征 (MDS) 和TP53突变的患者的治疗结果不佳. 在这些患者中,甲胺-甲胺 (DEC-C) 可能会提高整体存活率,而不是与亲肠道低甲剂 (HMA) 相比.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 带有TP53突变的骨髓发育综合征 (MDS) 与预后不佳有关.
- TP53突变对MDS治疗结果构成重大挑战.
研究的目的:
- 评估在TP53突变MDS的患者中,德西他 - cedazuridine (DEC-C) 的疗效.
- 为了比较TP53-突变的MDS患者的结果,他们接受了DEC-C治疗,而不是通过肠道输入的低甲基化剂 (HMA).
主要方法:
- 在MDS中对DEC-C的2/3期研究中的患者的分析.
- 将患者分为TP53野生型 (TP53wt),TP53单击和TP53多击组.
- 倾向性得分匹配,将DEC-C治疗的患者与接受单剂门HMA的患者进行比较.
主要成果:
- 多次感染TP53的患者表现出更高的复杂细胞遗传学发病率和更少的共同突变.
- TP53多次感染的患者有更高的缺乏反应率和更早的反应丧失率.
- 与TP53单击和TP53wt.相比,TP53多击患者的中位整体存活时间明显较低.
- 倾向匹配分析显示,在TP53突变的MDS中,DEC-C (13.1个月) 与肠道HMA (8.0个月) 的中位生存时间有所改善.
结论:
- TP53突变状态,特别是多重突变,影响MDS的反应和生存.
- 与标准的肠道HMA相比,DEC-C显示有潜力改善TP53突变的MDS患者的整体存活率.
- 需要进一步研究DEC-C在MDS中的特定TP53突变环境中的有效性.
相关概念视频
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


